Breaking News, Collaborations & Alliances

Compugen, Bayer in Cancer Drug Pact

Will pursue preclinical research program

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Compugen and Bayer HealthCare have signed a collaboration and license agreement for the research, development, and commercialization of antibody-based therapeutics for cancer immunotherapy against two of Compugen’s immune regulators. The two companies will jointly pursue a preclinical research program and Bayer will have full control of further development, along with worldwide commercialization rights for potential cancer therapies.   Compugen will receive a $10 million upfront payment, as much...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters